Brief: Travere Therapeutics Says FDA Extends Review Of SNDA For Filspari (Sparsentan) In FSGS
13/01/2026 18:26
Jan 13 (Reuters) - Travere Therapeutics Inc TVTX.O: TRAVERE THERAPEUTICS ANNOUNCES FDA EXTENDS REVIEW OF SNDA FOR FILSPARI® (SPARSENTAN) IN FSGS TRAVERE THERAPEUTICS INC - NEW PDUFA TARGET ACTION DATE SET FOR APRIL 13, 2026 TRAVERE THERAPEUTICS INC - NO ADDITIONAL SAFETY OR MANUFACTURING INFO REQUESTED FOR FILSPARI Source text: ID:nBw3C8WsLa Further company coverage: TVTX.O ((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Travere Therapeutics
See all newsBrief: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Travere Therapeutics - Receives USPTO Notice Of Allowance For Filspari Patent In FSGS
Brief: Travere Therapeutics Announces Planned Chief Executive Officer Transition
Brief: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule